These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 25433360)

  • 41. The emerging role of carfilzomib combination therapy in the management of multiple myeloma.
    Moreau P
    Expert Rev Hematol; 2014 Apr; 7(2):265-90. PubMed ID: 24521249
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Carfilzomib: a rare cause of posterior reversible encephalopathy syndrome.
    Katz-Agranov N; Padilla J; Scoon J; Cherian SV
    Ann Hematol; 2016 Oct; 95(11):1923-4. PubMed ID: 27477479
    [No Abstract]   [Full Text] [Related]  

  • 43. Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management.
    Wu P; Oren O; Gertz MA; Yang EH
    Curr Oncol Rep; 2020 Jun; 22(7):66. PubMed ID: 32514632
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Arterial Hypertension and Multiple Myeloma: Physiopathology and Cardiovascular Risk and 'Practical' Indications in Patients Receiving Carfilzomib.
    Milan A; Bruno G; Maffei I; Iannaccone A; Ravera A; Schiavone D; Veglio F
    Curr Hypertens Rev; 2019; 15(1):47-53. PubMed ID: 29886833
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity.
    Lendvai N; Tsakos I; Devlin SM; Schaffer WL; Hassoun H; Lesokhin AM; Landau H; Korde N; Mailankody S; Smith E; Chung DJ; Koehne G; Shah GL; Alexander A; Patel M; Ballagi A; Grundberg I; Giralt SA; Landgren O
    Leuk Lymphoma; 2018 Aug; 59(8):1981-1985. PubMed ID: 29308691
    [No Abstract]   [Full Text] [Related]  

  • 46. Proteasome inhibitors in the treatment of multiple myeloma.
    McBride A; Ryan PY
    Expert Rev Anticancer Ther; 2013 Mar; 13(3):339-58. PubMed ID: 23477520
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
    Highsmith KN; Chen SE; Horowitz S
    Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High dose carfilzomib proteasome inhibition induces anemia by oxidative hemolysis: A case series of 8 patients from a single centre.
    Rajagopal R; Bennett R; Liang J; Royle G
    Am J Hematol; 2019 Aug; 94(8):E215-E216. PubMed ID: 31066096
    [No Abstract]   [Full Text] [Related]  

  • 49. Proteasome Inhibitors as a Potential Cause of Heart Failure.
    Koulaouzidis G; Lyon AR
    Heart Fail Clin; 2017 Apr; 13(2):289-295. PubMed ID: 28279415
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib.
    Shen X; Wu C; Lei M; Yan Q; Zhang H; Zhang L; Wang X; Yang Y; Li J; Zhu Y; Chen L
    Cell Death Dis; 2021 Apr; 12(5):429. PubMed ID: 33931582
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta-analysis of randomized clinical trials.
    Das A; Dasgupta S; Gong Y; Shah UA; Fradley MG; Cheng RK; Roy B; Guha A
    Hematol Oncol; 2022 Apr; 40(2):233-242. PubMed ID: 34940983
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Carfilzomib-induced hemolysis is noticeably common but rarely shows features of thrombotic microangiopathy: A retrospective study.
    Kozlowski P; Kameran Behnam K; Uggla B; Åström M
    Eur J Haematol; 2020 Jun; 104(6):588-593. PubMed ID: 32115785
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Severe left atrial enlargement due to carfilzomib use in multiple myeloma.
    Dasanu CA; Plaxe SC; Popescu IM; Gupta V; Sontz E; Codreanu I
    J Oncol Pharm Pract; 2019 Dec; 25(8):2045-2048. PubMed ID: 30636528
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fatal pulmonary toxicity due to carfilzomib (Kyprolis™).
    Lataifeh AR; Nusair A
    J Oncol Pharm Pract; 2016 Oct; 22(5):720-4. PubMed ID: 26044587
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma.
    Squifflet P; Michiels S; Siegel D; Vij R; Jagannath S; Saad ED; Rajangam K; Ro SK; Buyse M
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):680-6. PubMed ID: 26482107
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis.
    Bishnoi R; Xie Z; Shah C; Bian J; Murthy HS; Wingard JR; Farhadfar N
    Cancer Med; 2021 Jan; 10(1):70-78. PubMed ID: 33169938
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of carfilzomib in the treatment of relapsed and (or) refractory multiple myeloma: a meta-analysis of data from clinical trials.
    Chen R; Chen B; Zhang X; Gao C
    Discov Med; 2016 Oct; 22(121):189-199. PubMed ID: 27875670
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Carfilzomib-associated tumor lysis syndrome.
    Shely RN; Ratliff PD
    Pharmacotherapy; 2014 May; 34(5):e34-7. PubMed ID: 24390940
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Not Available].
    Attucci I; Pilerci S; Messeri M; Pengue L; Tomasino G; Caroti L; Vannucchi AM; Antonioli E
    Cancer Rep (Hoboken); 2024 Oct; 7(10):e2163. PubMed ID: 39390755
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New orally active proteasome inhibitors in multiple myeloma.
    Allegra A; Alonci A; Gerace D; Russo S; Innao V; Calabrò L; Musolino C
    Leuk Res; 2014 Jan; 38(1):1-9. PubMed ID: 24239172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.